Cannabis-derived medical products face rigorous regulatory scrutiny requiring comprehensive purity assessment - unexpected nicotine contamination from tobacco exposure or processing compromises product quality and regulatory compliance. Nicotine quantification in CBD products ensures compliance with Swissmedic directives for cannabis-containing medical products, with GC-MS methodology providing specific identification and quantification in complex botanical matrices. Essential for quality control of CBD medical products demonstrating pharmaceutical-grade purity, demonstrating absence of nicotine contamination from co-cultivation with tobacco or processing equipment cross-contamination, and supporting regulatory submissions for cannabis-based therapeutics requiring comprehensive purity profiles. The GC-MS approach distinguishes nicotine from structural analogs and other alkaloids ensuring measurement specificity, while providing quantification below regulatory thresholds protecting patients from unexpected nicotine exposure. For medical cannabis products, nicotine contamination indicates cultivation problems where tobacco and cannabis grow in proximity, processing contamination where equipment handles both plant types, or raw material adulteration compromising product integrity. The testing supports pharmaceutical cannabis development ensuring botanical starting materials meet purity requirements, manufacturing validation confirming processing doesn't introduce nicotine contamination, and quality control releasing products meeting regulatory specifications. Swiss regulatory requirements for medical cannabis products demand documented nicotine testing supporting product authorization and ongoing batch release, making this analysis essential for market access in regulated medical cannabis markets.

Persistent environmental contaminants accumulate in ecosystems and human bodies creating long-term health concerns - PFAS compounds resist degradation while bioaccumulating, making their presence in medical devices increasingly problematic under evolving regulations. PFAS (per- and polyfluoroalkyl substances) analysis by LC-MS/MS addresses these persistent environmental contaminants of increasing regulatory concern, with methodology targeting expanding lists of restricted PFAS compounds. The analytical approach achieves sub-ppb detection limits required for compliance with stringent regulations limiting these "forever chemicals" that persist in environment and bioaccumulate in organizms. Critical for devices with fluoropolymer components including PTFE tubing and coatings, demonstrating compliance with emerging PFAS regulations restricting these persistent compounds, and addressing stakeholder concerns about environmental persistence even when health effects remain uncertain. For medical devices, PFAS testing validates that fluoropolymer processing adequately removes manufacturing residues including perfluorooctanoic acid (PFOA) used in PTFE production, alternative materials replacing restricted PFAS don't introduce equally problematic fluorinated compounds, and device use doesn't release PFAS at levels triggering regulatory concerns. The LC-MS/MS methodology provides sensitive detection distinguishing individual PFAS compounds in complex mixtures, quantifies both legacy PFAS like PFOS and PFOA plus replacement compounds, and accommodates regulatory method updates as restricted compound lists expand. Manufacturing validation ensures processing removes PFAS contamination from equipment and materials, incoming material screening verifies supplier claims about PFAS-free status, and product testing demonstrates compliance with market-specific regulations varying by region. The analysis proves essential as regulations tighten globally with EU restrictions expanding, US EPA limits strengthening, and environmental advocacy increasing pressure for PFAS elimination from consumer and medical products.

Manufacturing processes rely heavily on organic solvents for cleaning, extraction, and material processing - yet residual solvents left on medical devices cause cytotoxicity, tissue irritation, and systemic toxicity that threaten patient safety while compromising regulatory compliance. Isopropyl alcohol (IPA) serves as one of the most common solvents in medical device manufacturing, used for cleaning assembled devices, dissolving adhesives, and facilitating material processing, making residual IPA testing fundamental to safety validation. IPA residual solvent analysis following ISO 10993-12 and ISO 10993-18 employs extraction in DMF (dimethylformamide) followed by quantitative GC-FID analysis, providing sensitive detection of residual IPA that could cause adverse biological responses through direct tissue contact or systemic absorption. The extraction methodology ensures complete IPA recovery from device surfaces and absorbed within materials, while GC-FID quantification delivers precise measurement enabling comparison against established safety limits derived from toxicological data and pharmacopeial standards. Critical for validating manufacturing cleaning processes demonstrating adequate IPA removal after solvent-based operations, supporting biocompatibility assessment per ISO 10993-1 where residual solvents contribute to extractables profiles, and ensuring compliance with ICH Q3C guidelines limiting residual solvents in medical devices and pharmaceutical products. For implantable devices and blood-contacting applications, even trace IPA residues pose risks through chronic exposure or direct systemic introduction, requiring validated analytical methods proving residual levels remain below acceptable limits throughout shelf life. The GC-FID approach provides solvent-specific quantification distinguishing IPA from other volatile compounds, supports process validation demonstrating consistent solvent removal across manufacturing lots, and enables investigation of unexpected cytotoxicity potentially linked to inadequate solvent removal. Manufacturing quality control uses IPA testing for batch release decisions ensuring products meet residual solvent specifications, validates that drying or aeration processes adequately remove IPA, and demonstrates that sterilization doesn't trap solvents within sealed packages.